Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Lymphoma

  Free Subscription


Articles published in Haematologica

Retrieve available abstracts of 108 articles:
HTML format
Text format



Single Articles


    April 2019
  1. BELLEI M, Federico M
    The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective International T-Cell Project.
    Haematologica. 2019;104:e178.
    PubMed     Text format    


  2. DREGER P
    Comment to "The outcome of peripheral T-cell lymphoma patients failing first-line therapy".
    Haematologica. 2019;104:e178.
    PubMed     Text format    


  3. KUMAR A, Ying Z, Alperovich A, Dogan A, et al
    Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma.
    Haematologica. 2019;104:e163-e166.
    PubMed     Text format    


    March 2019
  4. BARRANCO GI, Fernandez S, Ona R, Gonzalez-Rincon J, et al
    Branched clonal evolution: nodal follicular lymphoma and primary diffuse large B-cell lymphoma of the central nervous system.
    Haematologica. 2019 Mar 19. pii: haematol.2018.214981.
    PubMed     Text format    


  5. CASADEI B, Broccoli A, Stefoni V, Pellegrini C, et al
    PD-1 blockade as bridge to allogenic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series.
    Haematologica. 2019 Mar 19. pii: haematol.2019.215962.
    PubMed     Text format    


  6. ROSSI D, Spina V, Bruscaggin A, Gaidano G, et al
    Liquid biopsy in lymphoma.
    Haematologica. 2019 Mar 7. pii: haematol.2018.206177.
    PubMed     Text format    


  7. GRANAI M, Ambrosio MR, Akarca A, Mundo L, et al
    Role of Epstein Barr virus in transformation of follicular lymphoma to diffuse large B-cell lymphoma: a case report and review of the literature.
    Haematologica. 2019 Mar 7. pii: haematol.2018.215053.
    PubMed     Text format    


  8. STEEN CB, Leich E, Myklebust JH, Lockmer S, et al
    A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy.
    Haematologica. 2019 Mar 7. pii: haematol.2018.209080.
    PubMed     Text format    


    February 2019
  9. LOVISA F, Binatti A, Coppe A, Primerano S, et al
    A high definition picture of key genes and pathways mutated in pediatric follicular lymphoma.
    Haematologica. 2019 Feb 28. pii: haematol.2018.211631.
    PubMed     Text format    


  10. D'AGARO T, Zucchetto A, Vit F, Bittolo T, et al
    A B-cell receptor-related gene signature predicts response to ibrutinib treatmeant in mantle cell lymphoma cell lines.
    Haematologica. 2019 Feb 28. pii: haematol.2018.212811.
    PubMed     Text format    


  11. GRAETZ D, Crews KR, Azzato EM, Singh RK, et al
    Leukemic presentation of ALK+ Anaplastic Large Cell Lymphoma with a novel partner, poly(A) binding protein cytoplasmic 1 (PABPC1), responding to single-agent crizotinib.
    Haematologica. 2019 Feb 28. pii: haematol.2018.215103.
    PubMed     Text format    


  12. HICKS SW, Tarantelli C, Wilhem A, Gaudio E, et al
    The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity than SAR3419 in CD19-positive lymphoma and leukemia models.
    Haematologica. 2019 Feb 7. pii: haematol.2018.211011.
    PubMed     Text format     Abstract available


  13. GONZALEZ-FARRE B, Ramis-Zaldivar JE, Salmeron-Villalobos J, Balague O, et al
    Burkitt-like lymphoma with 11q aberration: A germinal center derived lymphoma genetically unrelated to Burkitt lymphoma.
    Haematologica. 2019 Feb 7. pii: haematol.2018.207928.
    PubMed     Text format     Abstract available


    January 2019
  14. TARANTELLI C, Zhang L, Curti E, Gaudio E, et al
    The BTK inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.
    Haematologica. 2019 Jan 24. pii: haematol.2018.214759.
    PubMed     Text format    


  15. TOROSSIAN A, Broin N, Frentzel J, Daugrois C, et al
    Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death.
    Haematologica. 2019 Jan 24. pii: haematol.2017.181966.
    PubMed     Text format     Abstract available


  16. QDAISAT A, Al Soud R, Wu CC, Rojas Hernandez CM, et al
    Poor performance of D-Dimer in excluding venous thromboembolism among patients with lymphoma and leukemia.
    Haematologica. 2019 Jan 10. pii: haematol.2018.211466.
    PubMed     Text format    


  17. TAKEUCHI M, Miyoshi H, Asano N, Yoshida N, et al
    Human leukocyte antigen class II expression is a good prognostic factor of adult T-cell leukemia/lymphoma.
    Haematologica. 2019 Jan 10. pii: haematol.2018.205567.
    PubMed     Text format     Abstract available


  18. SILVA A, Bassim S, Sarkozy C, Mottok A, et al
    Convergence of risk prediction models in follicular lymphoma.
    Haematologica. 2019 Jan 3. pii: haematol.2018.209031.
    PubMed     Text format    


  19. SASSE S, Reddemann K, Diepstra A, Borchmann S, et al
    Programmed cell death protein1 (PD1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse after conventional chemotherapy and at relapse on anti-PD1 treatment.
    Haematologica. 2019;104:e45-e46.
    PubMed     Text format    


  20. TAYLOR JG, Clear A, Calaminici M, Gribben JG, et al
    Programmed cell death protein-1 (PD1) expression in the microenvironment of classical Hodgkin lymphoma is similar between favorable and adverse outcome and does not enrich over serial relapses with conventional chemotherapy.
    Haematologica. 2019;104:e42-e44.
    PubMed     Text format    


    December 2018
  21. QUALLS D, Abramson JS
    Advances in risk assessment and prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma.
    Haematologica. 2018 Dec 20. pii: haematol.2018.195834.
    PubMed     Text format     Abstract available


  22. BELHADJ M, Mansour D, Kaltenbach S, Deau-Fischer B, et al
    T-cell large granular lymphocyte leukemia transformation into aggressive T-cell lymphoma: a report of two cases with molecular characterization.
    Haematologica. 2018 Dec 20. pii: haematol.2018.205542.
    PubMed     Text format    


  23. PHILLIPS AA, Fields PA, Hermine O, Ramos JC, et al
    Mogamulizumab versus investigator choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma.
    Haematologica. 2018 Dec 20. pii: haematol.2018.205096.
    PubMed     Text format     Abstract available


  24. SEYMOUR JF, Marcus R, Davies A, Gallop-Evans E, et al
    Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.
    Haematologica. 2018 Dec 20. pii: haematol.2018.209015.
    PubMed     Text format     Abstract available


  25. ARESU L, Ferraresso S, Marconato L, Cascione L, et al
    New molecular and therapeutic insights into canine diffuse large B cell lymphoma elucidates the role of the dog as a model for human disease.
    Haematologica. 2018 Dec 13. pii: haematol.2018.207027.
    PubMed     Text format    


  26. DELAGE L, Manzoni D, Quinquenet C, Fontaine J, et al
    Molecular analysis of a CD19 negative diffuse large B cell lymphoma.
    Haematologica. 2018 Dec 13. pii: haematol.2018.203521.
    PubMed     Text format    


  27. UCHIDA A, Isobe Y, Asano J, Uemura Y, et al
    Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-protein-expression" lymphoma with MYC and BCL2 rearrangements.
    Haematologica. 2018 Dec 6. pii: haematol.2018.204958.
    PubMed     Text format     Abstract available


    November 2018
  28. RULE S, Dreyling M, Goy A, Hess G, et al
    Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow-up from a pooled analysis.
    Haematologica. 2018 Nov 15. pii: haematol.2018.205229.
    PubMed     Text format    


    October 2018
  29. HAGENBEEK A, Mooij H, Zijlstra J, Lugtenburg P, et al
    Phase 1 dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: the Transplant BRaVE study.
    Haematologica. 2018 Oct 31. pii: haematol.2018.196899.
    PubMed     Text format    


  30. BURKHARD R, Keller I, Arambasic M, Juskevicius D, et al
    TIRAP p.R81C is a novel lymphoma risk variant which enhances cell proliferation via NF-kappaB mediated signaling in B-cells.
    Haematologica. 2018 Oct 31. pii: haematol.2018.201590.
    PubMed     Text format     Abstract available


  31. BERGMANN AK, Fataccioli V, Castellano G, Martin-Garcia N, et al
    DNA methylation profiling identifies candidate genes for the pathogenesis of hepatosplenic T-cell lymphoma.
    Haematologica. 2018 Oct 18. pii: haematol.2018.196196.
    PubMed     Text format    


  32. CASAGRANDE N, Borghese C, Visser L, Mongiat M, et al
    CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth.
    Haematologica. 2018 Oct 11. pii: haematol.2018.196725.
    PubMed     Text format     Abstract available


  33. EVRARD SM, Pericart S, Grand D, Amara N, et al
    Targeted next generation sequencing reveals high mutation frequency of CREBBP, BCL2 and KMT2D in high-grade B-cell lymphoma with MYC and BCL2 and /or BCL6 rearrangements.
    Haematologica. 2018 Oct 11. pii: haematol.2018.198572.
    PubMed     Text format    


    September 2018
  34. KUBOTA-TANAKA M, Osumi T, Miura S, Tsujimoto H, et al
    B-lymphoblastic lymphoma with the TCF3-PBX1 fusion gene.
    Haematologica. 2018 Sep 27. pii: haematol.2018.199885.
    PubMed     Text format    


  35. LEIVONEN SK, Pollari M, Bruck O, Pellinen T, et al
    T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma.
    Haematologica. 2018 Sep 20. pii: haematol.2018.200105.
    PubMed     Text format     Abstract available


  36. OCHI Y, Hiramoto N, Yoshizato T, Ono Y, et al
    Clonally related diffuse large B-cell lymphoma and interdigitating dendritic cell sarcoma sharing MYC translocation.
    Haematologica. 2018 Sep 20. pii: haematol.2018.193490.
    PubMed     Text format    


  37. SCHUHMACHER B, Bein J, Rausch T, Benes V, et al
    JUNB, DUSP2, SGK1, SOCS1 and CREBBP are frequently mutated in T-cell/histiocyte rich large B-cell lymphoma.
    Haematologica. 2018 Sep 13. pii: haematol.2018.203224.
    PubMed     Text format     Abstract available


  38. STRATI P, Fanale M, Oki Y, Turturro F, et al
    Rituximab with ABVD vs ABVD for advanced stage high-risk classical Hodgkin lymphoma: a randomized phase II study.
    Haematologica. 2018 Sep 6. pii: haematol.2018.199844.
    PubMed     Text format    


  39. EYRE TA, Walter HS, Iyengar S, Follows G, et al
    Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy.
    Haematologica. 2018 Sep 6. pii: haematol.2018.198812.
    PubMed     Text format    


    August 2018
  40. GRESSIN R, Daguindau N, Tempescul A, Moreau A, et al
    A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first line treatment of older patients with mantle cell lymphoma.
    Haematologica. 2018 Aug 31. pii: haematol.2018.191429.
    PubMed     Text format     Abstract available


  41. KINOSHITA S, Ishida T, Ito A, Narita T, et al
    Cyclin-dependent kinase 9 as a potential specific molecular target in NK cell leukemia/lymphoma.
    Haematologica. 2018 Aug 3. pii: haematol.2018.191395.
    PubMed     Text format     Abstract available


  42. MENSAH AA, Cascione L, Gaudio E, Tarantelli C, et al
    Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma.
    Haematologica. 2018 Aug 3. pii: haematol.2018.191684.
    PubMed     Text format     Abstract available


  43. SASSE S, Reddemann K, Diepstra A, Oschlies I, et al
    Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment.
    Haematologica. 2018 Aug 3. pii: haematol.2018.196279.
    PubMed     Text format    


  44. DE SMEDT R, Peirs S, Morscio J, Matthijssens F, et al
    Preclinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma.
    Haematologica. 2018 Aug 3. pii: haematol.2018.199257.
    PubMed     Text format    


  45. MELANI C, Roschewski M, Wilson WH
    End-of-treatment and serial PET imaging has prognostic value and clinical utility in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R - Response to Adams et al.
    Haematologica. 2018;103:e382.
    PubMed     Text format    


  46. ADAMS HJA, Kwee TC
    Unproven value of end-of-treatment and serial follow-up FDG-PET in primary mediastinal B-cell lymphoma.
    Haematologica. 2018;103:e380-e381.
    PubMed     Text format    


    July 2018
  47. POLLARI M, Bruck O, Pellinen T, Vahamurto P, et al
    PD-L1+ tumor-associated macrophages and PD-1+ tumor infiltrating lymphocytes predict survival in primary testicular lymphoma.
    Haematologica. 2018 Jul 19. pii: haematol.2018.197194.
    PubMed     Text format     Abstract available


  48. DE CHARETTE M, Houot R
    Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy.
    Haematologica. 2018 Jul 13. pii: haematol.2017.184192.
    PubMed     Text format     Abstract available


  49. VILLA D, Sehn LH, Aquino-Parsons C, Tonseth P, et al
    Interim PET-directed therapy in limited stage Hodgkin lymphoma initially treated with ABVD.
    Haematologica. 2018 Jul 12. pii: haematol.2018.196782.
    PubMed     Text format    


  50. ARAF S, Wang J, Ashton-Key M, Korfi K, et al
    Transmission of diffuse large B cell lymphoma by an allogeneic stem-cell transplant.
    Haematologica. 2018 Jul 5. pii: haematol.2018.196907.
    PubMed     Text format    


    June 2018
  51. AMBROSIO MR, Lazzi S, Lo Bello G, Santi R, et al
    MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients.
    Haematologica. 2018 Jun 28. pii: haematol.2018.195958.
    PubMed     Text format    


  52. RECASENS-ZORZO C, Cardesa-Salzmann T, Petazzi P, Ros-Blanco L, et al
    Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma.
    Haematologica. 2018 Jun 28. pii: haematol.2017.180505.
    PubMed     Text format     Abstract available


  53. EPSTEIN MM, Rosner B, Breen EC, Batista JL, et al
    Pre-diagnosis plasma immune markers and risk of non-Hodgkin lymphoma in two prospective cohort studies.
    Haematologica. 2018 Jun 21. pii: haematol.2017.183236.
    PubMed     Text format     Abstract available


  54. MCPHAIL ED, Maurer MJ, Macon WR, Feldman AL, et al
    Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements.
    Haematologica. 2018 Jun 14. pii: haematol.2018.190157.
    PubMed     Text format     Abstract available


  55. PEREZ-SALVIA M, Aldaba E, Vara Y, Fabre M, et al
    In vitro and in vivo activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma.
    Haematologica. 2018 Jun 7. pii: haematol.2018.189241.
    PubMed     Text format    


    May 2018
  56. ESKELUND CW, Albertsson-Lindblad A, Kolstad A, Laurell A, et al
    Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma.
    Haematologica. 2018 May 24. pii: haematol.2018.194399.
    PubMed     Text format    


  57. STORTI S, Spina M, Pesce EA, Salvi F, et al
    Rituximab plus Bendamustine as front line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin's lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi.
    Haematologica. 2018 May 10. pii: haematol.2017.186569.
    PubMed     Text format     Abstract available


  58. TRNENY M, Verhoef G, Dyer MJ, Yehuda DB, et al
    A Phase 2 multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy.
    Haematologica. 2018 May 10. pii: haematol.2017.168401.
    PubMed     Text format     Abstract available


  59. MELANI C, Advani R, Roschewski M, Walters KM, et al
    End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted-EPOCH-R: A paradigm shift in clinical decision making.
    Haematologica. 2018 May 10. pii: haematol.2018.192492.
    PubMed     Text format     Abstract available


    April 2018
  60. STRATI P, Chihara D, Oki Y, Fayad LE, et al
    A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
    Haematologica. 2018 Apr 5. pii: haematol.2018.187617.
    PubMed     Text format    


  61. KUPPERS R
    CD83 in Hodgkin lymphoma.
    Haematologica. 2018;103:561-562.
    PubMed     Text format    


    March 2018
  62. BELLEI M, Foss FM, Shustov AR, Horwitz SM, et al
    The outcome of peripheral T-cell lymphoma patients failing first line therapy: a report from the prospective, international T-Cell project.
    Haematologica. 2018 Mar 29. pii: haematol.2017.186577.
    PubMed     Text format     Abstract available


  63. HORN H, Kohler C, Witzig R, Kreuz M, et al
    Gene expression profiling reveals a close relationship between follicular lymphoma grade 3A and 3B, but distinct profiles of follicular lymphoma grade 1 and 2.
    Haematologica. 2018 Mar 22. pii: haematol.2017.181024.
    PubMed     Text format     Abstract available


  64. ALIG S, Jurinovic V, Pastore A, Bararia D, et al
    Impact of age on genetics and treatment efficacy in follicular lymphoma.
    Haematologica. 2018 Mar 15. pii: haematol.2018.187773.
    PubMed     Text format    


  65. MAFFINI E, Anderson LD Jr., Sandmaier BM, Green DJ, et al
    Nonmyeloablative allogeneic hematopoietic cell transplantation for relapsed or refractory Waldenstrom macroglobulinemia: Evidence for a graft-versus-lymphoma effect.
    Haematologica. 2018 Mar 15. pii: haematol.2017.184176.
    PubMed     Text format    


  66. NIJLAND ML, Koens L, Pals ST, Berge IJMT, et al
    Clinicopathological characteristics of T-cell non-Hodgkin lymphoma arising in patients with immunodeficiencies: a single-center case series of 25 patients and a review of the literature.
    Haematologica. 2018;103:486-496.
    PubMed     Text format     Abstract available


  67. LEMONNIER F, Poullot E, Dupuy A, Couronne L, et al
    Loss of 5-hydroxymethylcytosine is a frequent event in peripheral T-cell lymphomas.
    Haematologica. 2018;103:e115-e118.
    PubMed     Text format    


  68. WANG X, Chen Z, Mishra AK, Silva A, et al
    Chemotherapy-induced differential cell cycle arrest in B-cell lymphomas affects their sensitivity to Wee1 inhibition.
    Haematologica. 2018;103:466-476.
    PubMed     Text format     Abstract available


    February 2018
  69. BOMBEN R, Ferrero S, D'Agaro T, Dal Bo M, et al
    A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the "Fondazione Italiana Linfomi" MCL-0208 trial.
    Haematologica. 2018 Feb 22. pii: haematol.2017.184325.
    PubMed     Text format     Abstract available


  70. BIRSEN R, Willems L, Pallud J, Blanc E, et al
    Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients.
    Haematologica. 2018 Feb 22. pii: haematol.2017.185843.
    PubMed     Text format    


  71. RIMSZA LM, Li H, Braziel RM, Spier CM, et al
    Impact of histologic grading on survival in the SWOG S0016 follicular lymphoma cohort.
    Haematologica. 2018 Feb 22. pii: haematol.2017.175059.
    PubMed     Text format     Abstract available


  72. SUEHARA Y, Sakata-Yanagimoto M, Hattori K, Nanmoku T, et al
    Liquid biopsy for the identification of intravascular large B-cell lymphoma.
    Haematologica. 2018 Feb 22. pii: haematol.2017.178830.
    PubMed     Text format     Abstract available


  73. ARVIDSSON G, Henriksson J, Sander B, Wright AP, et al
    Mixed-species RNAseq analysis of human lymphoma cells adhering to mouse stromal cells identifies a core gene set that is also differentially expressed in the lymph node microenvironment of mantle cell lymphoma and chronic lymphocytic leukemia patients
    Haematologica. 2018 Feb 15. pii: haematol.2017.182048.
    PubMed     Text format     Abstract available


  74. SCHOMMERS P, Gillor D, Hentrich M, Wyen C, et al
    Incidence and risk factors for relapses in HIV-associated non-Hodgkin-lymphoma as observed in the German HIV-related lymphoma cohort study.
    Haematologica. 2018 Feb 8. pii: haematol.2017.180893.
    PubMed     Text format     Abstract available


  75. SHALABI H, Kraft IL, Wang HW, Yuan CM, et al
    Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma.
    Haematologica. 2018 Feb 1. pii: haematol.2017.183459.
    PubMed     Text format     Abstract available


    January 2018
  76. FUJI S, Utsunomiya A, Inoue Y, Miyagi T, et al
    Outcomes of patients with relapsed aggressive adult T-cell leukemia-lymphoma: clinical effectiveness of anti-CCR4 antibody and allogeneic hematopoietic stem cell transplantation.
    Haematologica. 2018 Jan 25. pii: haematol.2017.184564.
    PubMed     Text format    


  77. LI Z, Ju X, Lee K, Clarke C, et al
    CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma.
    Haematologica. 2018 Jan 19. pii: haematol.2017.178384.
    PubMed     Text format     Abstract available


  78. VAN DEN NESTE E, Andre M, Gastinne T, Stamatoullas A, et al
    Phase II study of oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma.
    Haematologica. 2018 Jan 19. pii: haematol.2017.180554.
    PubMed     Text format     Abstract available


  79. JI MM, Huang YH, Huang JY, Wang ZF, et al
    Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified.
    Haematologica. 2018 Jan 5. pii: haematol.2017.182444.
    PubMed     Text format     Abstract available


    December 2017
  80. KNORR F, Damm-Welk C, Ruf S, Singh VK, et al
    Blood cytokine concentrations of pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma patients.
    Haematologica. 2017 Dec 14. pii: haematol.2017.177972.
    PubMed     Text format     Abstract available


  81. BOBILLO S, Abrisqueta P, Carpio C, Raheja P, et al
    Promising activity of selinexor in the treatment of a patient with refractory diffuse large B-cell lymphoma and central nervous system involvement.
    Haematologica. 2017 Dec 14. pii: haematol.2017.181636.
    PubMed     Text format    


  82. AUNER HW, Iacobelli S, Sbianchi G, Knol-Bout C, et al
    Melphalan 140mg/m2 or 200mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party.
    Haematologica. 2017 Dec 7. pii: haematol.2017.181339.
    PubMed     Text format     Abstract available


    November 2017
  83. TRACY SI, Habermann TM, Feldman AL, Maurer MJ, et al
    Outcomes among US patients with diffuse large B cell lymphoma are independent of tumor Epstein Barr virus positivity or immunosuppression.
    Haematologica. 2017 Nov 23. pii: haematol.2017.176511.
    PubMed     Text format     Abstract available


  84. COUTRE S, Tedeschi A, Robak T, Barr PM, et al
    Survival adjusting for crossover: phase 3 study of ibrutinib vs chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Haematologica. 2017 Nov 23. pii: haematol.2017.175380.
    PubMed     Text format    


  85. BOSCH M, Akhter A, Chen BE, Mansoor A, et al
    A bio-clinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma.
    Haematologica. 2017 Nov 2. pii: haematol.2017.179309.
    PubMed     Text format     Abstract available


  86. NG SB, Chung TH, Kato S, Nakamura S, et al
    EBV-associated primary nodal T/NK-cell lymphoma shows distinct molecular signature and copy number changes.
    Haematologica. 2017 Nov 2. pii: haematol.2017.180430.
    PubMed     Text format     Abstract available


    October 2017
  87. RUDELIUS M, Rosenfeldt MT, Leich E, Rauert-Wunderlich H, et al
    Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment.
    Haematologica. 2017 Oct 27. pii: haematol.2017.177162.
    PubMed     Text format     Abstract available


  88. LANDMANN E, Burkhardt B, Zimmermann M, Meyer U, et al
    Results and conclusions of the European Intergroup EURO-LB02 Trial in children and adolescents with lymphoblastic lymphoma.
    Haematologica. 2017 Oct 5. pii: haematol.2015.139162.
    PubMed     Text format     Abstract available


    September 2017
  89. YOUNES A, Salles G, Martinelli G, Bociek RG, et al
    Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed and refractory non-Hodgkin lymphoma.
    Haematologica. 2017 Sep 29. pii: haematol.2017.169656.
    PubMed     Text format     Abstract available


  90. LUGTENBURG P, Avivi I, Berenschot H, Ilhan O, et al
    Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study.
    Haematologica. 2017 Sep 21. pii: haematol.2017.173583.
    PubMed     Text format     Abstract available


  91. EICHENAUER DA, Becker I, Monsef I, Chadwick N, et al
    Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: A systematic review and meta-analysis of randomized clinical trials.
    Haematologica. 2017 Sep 14. pii: haematol.2017.167478.
    PubMed     Text format     Abstract available


    August 2017
  92. OKI Y, Kelly KR, Flinn I, Patel MR, et al
    CUDC-907 in relapsed/refractory diffuse Large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase 1 trial.
    Haematologica. 2017 Aug 31. pii: haematol.2017.172882.
    PubMed     Text format     Abstract available


  93. VIDAL-CRESPO A, Rodriguez V, Matas-Cespedes A, Lee E, et al
    The BTK inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on the NF-kappaB mutational status.
    Haematologica. 2017 Aug 24. pii: haematol.2017.168930.
    PubMed     Text format    


  94. BROCCOLI A, Pellegrini C, Di Rocco A, Puccini B, et al
    Italian real life experience with brentuximab vedotin: results of a large observational study on 40 relapsed/refractory systemic anaplastic large cell lymphoma.
    Haematologica. 2017 Aug 3. pii: haematol.2017.171355.
    PubMed     Text format     Abstract available


    July 2017
  95. MONDELAERS V, Suciu S, De Moerloose B, Ferster A, et al
    Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951.
    Haematologica. 2017 Jul 27. pii: haematol.2017.165845.
    PubMed     Text format     Abstract available


  96. JALLADES L, Baseggio L, Sujobert P, Huet S, et al
    Exome sequencing identifies recurrent BCOR gene alterations and the absence of KLF2, TNFAIP3 and MYD88 mutations in splenic diffuse red pulp small B-cell lymphoma.
    Haematologica. 2017 Jul 27. pii: haematol.2016.160192.
    PubMed     Text format     Abstract available


  97. JAIS JP, Molina TJ, Ruminy P, Gentien D, et al
    Reliable subtype classification of diffuse large B-Cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay.
    Haematologica. 2017 Jul 4. pii: haematol.2017.166827.
    PubMed     Text format    


  98. FERRERO S, Dreyling M
    Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach?
    Haematologica. 2017;102:1133-1136.
    PubMed     Text format    


    June 2017
  99. VAN DE KROGT JA, Vanden Bempt M, Finalet Ferreiro J, Mentens N, et al
    ALK-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene.
    Haematologica. 2017 Jun 28. pii: haematol.2016.146571.
    PubMed     Text format     Abstract available


  100. EHRENTRAUT S, Nagel S, Pommerenke C, Dirks WG, et al
    Peripheral T-cell lymphoma cell line T8ML-1 highlights conspicuous targeting of PVRL2 by t(14;19)(q11.2;q13.3).
    Haematologica. 2017 Jun 28. pii: haematol.2017.168203.
    PubMed     Text format    


  101. BRON D, Aurer I, Andre MPE, Bonnet C, et al
    Unmet needs in the scientific approach to older patients with lymphoma.
    Haematologica. 2017;102:972-975.
    PubMed     Text format    


    May 2017
  102. CAMPOS-MARTIN Y, Martinez N, Martinez-Lopez A, Cereceda L, et al
    Clinical and diagnostic relevance of NOTCH2 and KLF2 mutations in splenic marginal zone lymphoma.
    Haematologica. 2017 May 18. pii: haematol.2016.161711.
    PubMed     Text format    


  103. DAVID A, Arnaud N, Fradet M, Lascaux H, et al
    c-Myc dysregulation is a co-transforming event for nuclear factor-kappaB activated B cells.
    Haematologica. 2017;102:883-894.
    PubMed     Text format     Abstract available


    April 2017
  104. STEVENS WBC, Mendeville M, Redd R, Clear AJ, et al
    Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: A study by the Lunenburg Lymphoma Biomarker Consortium.
    Haematologica. 2017 Apr 14. pii: haematol.2017.165415.
    PubMed     Text format     Abstract available


  105. NOBLE RA, Bell N, Blair H, Sikka A, et al
    Inhibition of monocarboxylate transporter 1 by AZD3965 as a novel therapeutic approach for the treatment of diffuse large B-cell lymphoma and Burkitt lymphoma.
    Haematologica. 2017 Apr 6. pii: haematol.2016.163030.
    PubMed     Text format     Abstract available


  106. BI C, Zhang X, Lu T, Zhang X, et al
    Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas.
    Haematologica. 2017;102:755-764.
    PubMed     Text format     Abstract available


    March 2017
  107. FUJI S, Yamaguchi T, Inoue Y, Utsunomiya A, et al
    Development of a modified prognostic index of patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger: a possible risk-adapted management strategies including allogeneic transplantation.
    Haematologica. 2017 Mar 24. pii: haematol.2017.164996.
    PubMed     Text format     Abstract available


  108. DENG AL, Kim YR, Lichtenstein EA, O'Connor OA, et al
    Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B cell lymphoma leg type with mutant MYD88 and wildtype CD79.
    Haematologica. 2017 Mar 24. pii: haematol.2016.161893.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: